Effect of Kampo medicine on those who plan to receive the new COVID-19 vaccine

Phase 2

Recruiting

• Conditions: Those who are scheduled to receive the new corona vaccine; new corona vaccination

• Registration Number: JPRN-jRCTs031230190
• Lead Sponsor: amiki Takao

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-06-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1.Adults aged between 18 and 40 at the time of obtaining consent
2.Those who are eligible for the new corona vaccine and can be vaccinated

Exclusion Criteria

1.Those who are taking other Kampo medicines on the day of vaccination
2.Those who have a history of adverse events such as allergies to Kampo medicines in the past
3.Those who are pregnant, may be pregnant, have given birth within 28 days, or are breastfeeding
4.Those who have been diagnosed with arrhythmia, coronary artery disease, heart disease such as heart failure, renal failure, thyroid dysfunction, or prostatic hyperplasia
5.Those with symptoms of swelling, dysuria, and palpitations
6.Those who have uncontrolled hypertension (systolic blood pressure of 150 mmHg or more or diastolic blood pressure of 90 mmHg or more)
7.Extremely thin (BMI less than 18.5)
8.KPS 70 or less (KPS 70 = able to take care of themselves but unable to perform normal activities/work)
9.Others judged by the principal investigator or co-investigator to be inappropriate for the safe conduct of this study (physical weakness, etc.)

Study & Design

• Study Type: Interventional
• Study Design: Not specified